NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02684006,A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),https://clinicaltrials.gov/study/NCT02684006,,COMPLETED,"This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma",YES,Renal Cell Cancer,DRUG: Avelumab (MSB0010718C)|DRUG: Axitinib (AG-013736)|DRUG: Sunitinib,"Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants, PFS: time from the date of randomization to the date of the first documentation of progressive disease (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1) or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20 percent (%), increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute more than (\>) of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression., From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)|Overall Survival (OS) in PD-L1 Positive Participants, OS was defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method., From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)","PFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression, PFS: time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression., From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)|OS in Participants Irrespective of PD-L1 Expression, OS was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method., From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)|Percentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression, OR was defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method., From date of randomization until PD (maximum up to approximately 26 months)|Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression, OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by investigator recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method., From date of randomization until PD (maximum up to approximately 89 months)|Percentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression, DC was defined as a best overall response of CR, PR, non-CR/non-PD or stable disease (SD) according to RECIST v1.1 as assessed by BICR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds., From date of randomization until PD (maximum up to approximately 26 months)|Percentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression, DC was defined as a best overall response of CR, PR, non-CR/non-PD or SD according to RECIST v1.1 as assessed by investigator. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds., From date of randomization until PD (maximum up to approximately 89 months)|Time to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression, TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by BICR (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed., From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)|TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression, TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by investigator (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed., From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 89 months)|Duration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression, BICR assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression assessed by BICR or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression., From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)|DR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression, Investigator assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression (PD) assessed by investigator or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression., From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 89 months)|PFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression, Investigator assessed PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression., From date of randomization until PD, whichever occurred first (maximum up to approximately 89 months)|Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression, PFS2 is defined as the time (in months) from randomization to discontinuation of next-line treatment after first objective disease progression by investigator assessment, second objective disease progression by investigator assessment after initiation of next-line treatment, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression., From date of randomization until PD or death, whichever occurred first (maximum up to approximately 89 months)|Number of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version (V) 4.03, An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period (time from the first dose of study treatment through minimum \[30 days+last dose of study treatment, start day of new anti-cancer drug therapy-1 day\]). As per NCI-CTCAE v4.03, Grade(G)1:asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life \\(ADL); G3: severe or medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; G4: life-threatening consequence, urgent intervention indicated; G5: death related to AE., From first dose of study drug to 90 days after last administration of study drug|Number of Participants With Laboratory Abnormalities Based on NCI-CTCAE V4.03, From first dose of study drug to 90 days after last administration of study drug|Number of Participants With Vital Signs Abnormalities, From first dose of study drug to 90 days after last administration of study drug|Time to Treatment Discontinuation/Failure Due to Toxicity, Time to treatment discontinuation/ failure due to toxicity is defined as the time from first dose of study treatment to discontinuation of study treatment due to an adverse event or death due to study treatment toxicity., From first dose of study treatment until discontinuation of study treatment|Number of Participants Who Discontinued Treatment Due to Toxicity, From first dose of study treatment until discontinuation of study treatment|Trough Plasma Concentration (Ctrough) of Avelumab, Predose concentration during multiple dosing., Pre dose (0 hour) on Day 1, 15 and 29 of Cycle 1, Day 1 and 29 of Cycles 2, 3, 4 and Day 1 of Cycle 6|Ctrough of Axitinib, Predose concentration during multiple dosing., Pre dose (0 hour) on day 15 and 29 of cycle 1 (each cycle= 6 weeks)|Maximum Plasma Concentration (Cmax) of Axitinib, 2 hours post-dose on Day 1, pre-dose and 2 hours post dose on Days 15 and 29 of Cycle 1|Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue, Tumor biospecimens from pre-treatment tissue samples were analyzed by immunohistochemistry for PD-L1 biomarker expression. Number of participants with positive PD-L1 biomarker expression are reported in this outcome measure., At screening|PFS in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups, PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression., From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)|Percentage of Participants With OR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups, OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed., From date of randomization until PD (maximum up to approximately 26 months)|Percentage of Participants With DC in Biomarker-Positive Subgroup, DC was defined as a best overall response of CR, PR, or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. SD was defined as PR that the sum increases by less than 20% from the nadir, (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds., From date of randomization until PD or death, whichever occurred first (maximum up to approximately 26 months)|TTR in Biomarker-Positive Subgroup, TTR was defined as the time from randomization to the first documentation of objective tumor response (CR or PR) according to RECIST v1.1 which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed., From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)|DR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups, DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause, whichever occurred first. As per RECIST version 1.1, CR: disappearance of all target and non-target lesions, and sustained for at least 4 weeks. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 mm. PR: at least 30%\< in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD: defined as at least a 20% \> in sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. Appearance of one or more new lesions was also considered progression., From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)|Number of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) of Avelumab When Used in Combination With Axitinib, From start of treatment until 30 days after the end of avelumab treatment (maximum up to approximately 89 months)|Time to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS), TTD was defined as the time from date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS. FKSI was used to assess symptoms and quality of life (QoL) for those diagnosed with advanced kidney cancer and it consisted of 19 questions. A 9-item subscale of the FKSI known as FKSI-Disease Related Symptoms subscale (FKSI-DRS). This subscale included 9 items: lack of energy, pain, losing weight, bone pain, fatigue, shortness of breath, coughing, bothered by fevers, and hematuria. Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher score indicated greater presence of symptoms., Date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS (maximum up to approximately 26 months)|Change From Baseline in European Quality of Life (EuroQol) 5-Dimension 5 Levels (EQ-5D-5L) Utility Score, EQ-5D-5L is a 5-item participant-completed questionnaire designed to assess health status in terms of a single utility score. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Overall scores ranged from 0 to 1, with low scores representing a higher level of dysfunction. Published UK weights were used to create a single summary utility score. Utility scores range from -0.594 to 1, with higher scores representing better health status., Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)|Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Score, EQ-VAS records the participant's self-rated health status from 0 (worst imaginable health status) to 100 (best imaginable health status), where higher scores indicated better health status., Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)",,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,886,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,B9991003|2015-002429-20|JAVELIN RENAL 101,2016-03-23,2023-08-31,2024-06-26,2016-02-17,2024-10-29,2024-10-29,"Southern Cancer Center, Daphne, Alabama, 36526, United States|Southern Cancer Center, Mobile, Alabama, 36607, United States|Southern Cancer Center, Mobile, Alabama, 36608, United States|Tower Hematology Oncology Medical Group, Beverly Hills, California, 90211, United States|City of Hope National Medical Center, Duarte, California, 91010, United States|City of Hope, Duarte, California, 91010, United States|Keck Hospital of USC, Los Angeles, California, 90033, United States|LAC + USC Medical Center, Los Angeles, California, 90033, United States|Los Angeles General Medical Center, Los Angeles, California, 90033, United States|USC IDS Pharmacy, Los Angeles, California, 90033, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Cedars-Sinai Advanced Health Sciences Pavilion, Los Angeles, California, 90048, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, 90048, United States|Cedars-Sinai, Los Angeles, California, 90048, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, 80012, United States|Anschutz Cancer Center Pavilion Pharmacy, Aurora, Colorado, 80045, United States|University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|University of Colorado Hospital - Clinical Trials Office (CTO), Aurora, Colorado, 80045, United States|University of Colorado Hospital, Aurora, Colorado, 80045, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, 80907, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Investigational Drug Service- Emory University, Atlanta, Georgia, 30322, United States|The Emory Clinic, Atlanta, Georgia, 30322, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|East Jefferson General Hospital, Metairie, Louisiana, 70006, United States|East Jefferson Hematology-Oncology Metairie Physician Service Inc., Metairie, Louisiana, 70006, United States|New England Cancer Specialists, Kennebunk, Maine, 04043, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|New England Cancer Specialists, Topsham, Maine, 04086, United States|Oncology Investigational Drug Services- The Sidney Kimmel Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, 21231, United States|The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|John Hopkins Hospital, Baltimore, Maryland, 21287, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21287, United States|MedStar Health Cardiology Associates, LLC., Brandywine, Maryland, 20613, United States|Cardiology Associates, P.C., Chester, Maryland, 21619, United States|Massachusetts General Hospital (MGH), Boston, Massachusetts, 02114, United States|Massachusetts General Hospital Clinical Trials Pharmacy, Boston, Massachusetts, 02114, United States|Brigham & Women's Hospital, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, 02215, United States|Beth Israel Deaconess Medical Center Pharmacy - BIDMC, Boston, Massachusetts, 02215, United States|Dana - Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Baystate Franklin Medical Center, Greenfield, Massachusetts, 01301, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Barnes-Jewish Hospital, Siteman Cancer Center - West County, Creve Coeur, Missouri, 63141, United States|Barnes-Jewish Hospital, Siteman Cancer Center, Saint Louis, Missouri, 63110, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, 63110, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Barnes-Jewish Hospital, Siteman Cancer Center - South County, Saint Louis, Missouri, 63129, United States|Barnes-Jewish Hospital, Siteman Cancer Center - St. Peters, Saint Peters, Missouri, 63376, United States|St. Vincent HealthCare, Billings, Montana, 59101, United States|St. Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 75063, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|New York Oncology Hematology, P.C., Albany, New York, 12206, United States|New York Oncology Hematology, PC, Albany, New York, 12208, United States|New York Oncology Hematology, P.C., Clifton Park, New York, 12065, United States|Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City, New York, 11101, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|NYU Investigational Pharmacy, New York, New York, 10016, United States|NYU Langone Medical Center, New York, New York, 10016, United States|MSKCC-Monitoring Suite, New York, New York, 10017, United States|Evelyn H. Lauder Breast and Imaging Center, New York, New York, 10065, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, 10065, United States|Stony Brook University, Stony Brook, New York, 11794-7007, United States|Stony Brook University-Cancer Center, Stony Brook, New York, 11794-7263, United States|Stony Brook University, Stony Brook, New York, 11794, United States|Novant Health Oncology Specialists, Kernersville, North Carolina, 27284, United States|Novant Health Oncology Specialists, Lexington, North Carolina, 27295, United States|Novant Health Oncology Specialists, Mount Airy, North Carolina, 27030, United States|Novant Health Oncology Specialists, North Wilkesboro, North Carolina, 28659, United States|Novant Health Clinical Research Onocolgy, Winston-Salem, North Carolina, 27103, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, 27103, United States|Novant Health Winston Salem Health Care, Winston-Salem, North Carolina, 27103, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic Investigational Pharmacy, Cleveland, Ohio, 44195, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|James Cancer Hospital and Solove Research Institute, Columbus, Ohio, 43210, United States|The Ohio State University - GU Clinic, Columbus, Ohio, 43210, United States|The Ohio State University, Columbus, Ohio, 43210, United States|Cancer Care Associates Medical Oncology, Allentown, Pennsylvania, 18104, United States|St.Luke's Hospital-Allentown Campus, Allentown, Pennsylvania, 18104, United States|Cancer Care Associate Medical Oncology, Bethlehem, Pennsylvania, 18015, United States|St. Lukes University Health Network, Bethlehem, Pennsylvania, 18015, United States|St.Luke's University Health Network, Bethlehem, Pennsylvania, 18015, United States|St.Luke's Cancer Center Anderson, Easton, Pennsylvania, 18045, United States|St.Luke's Hospital-Anderson Campus, Easton, Pennsylvania, 18045, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Investigational Drug Service, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|St.Luke's Quakertown Hospital, Quakertown, Pennsylvania, 18951, United States|Memorial Hospital, York, Pennsylvania, 17405, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232-6307, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, 37232, United States|Oncology IDS Pharmacy, Nashville, Tennessee, 37232, United States|Vanderbilt University Oncology Pharmacy, Nashville, Tennessee, 37232, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Texas Oncology - Gulf Coast, Houston, Texas, 77024, United States|Texas Oncology- Memorial City, Houston, Texas, 77024, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Investigational Product Center (IPC), Irving, Texas, 75063, United States|Investigational Products Center (IPC), Irving, Texas, 75063, United States|Investigational Products Center (lPC), Irving, Texas, 75063, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, 75063, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, 79410, United States|Rainier Hematology-Oncology, PC, Puyallup, Washington, 98373, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, 98109, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, 98405, United States|Macquarie University Hospital Pharmacy, Macquarie University, New South Wales, 2109, Australia|Macquarie University, Macquarie University, New South Wales, 2109, Australia|Nuclear Medicine Department, Randwick, New South Wales, 2031, Australia|Pharmacy Department, Clinical Trials, Randwick, New South Wales, 2031, Australia|Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia|Spectrum Medical Imaging, Randwick, New South Wales, 2031, Australia|Division of Cancer Services, Woolloongabba, Queensland, 4102, Australia|BHS Diagnostic Services, Ballarat, Victoria, 3350, Australia|Lake Imaging, Ballarat, Victoria, 3350, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Eastern Health, Box Hill, Victoria, 3128, Australia|Monash Health Translational Precinct, Monash Medical Centre, Clayton, Victoria, 3168, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Monash Cancer Centre, East Bentleigh, Victoria, 3165, Australia|Moorabbin Radiology, East Bentleigh, Victoria, 3165, Australia|Slade Health, Mount Waverley, Victoria, 3149, Australia|Ballarat Day Procedure Centre, Wendouree, Victoria, 3355, Australia|Ballarat Oncology & Haematology Services, Wendouree, Victoria, 3355, Australia|Nova Pharmacy, Wendouree, Victoria, 3355, Australia|SKG Radiology, Murdoch, Western Australia, 6050, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|SKG Radiology, Murdoch, Western Australia, 6150, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, 6150, Australia|EPIC Pharmacy Murdoch, Perth, Western Australia, 6150, Australia|Krankenhaus der Barmherzigen Schwestern Wien, Wien, 1060, Austria|Medizinische Universitaet Wien, Wien, 1090, Austria|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium|UZ Gent, Gent, 9000, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|CHU de Liège, Liège, 4000, Belgium|Foothills Medical Centre, Calgary, Alberta, T2N 2T9, Canada|Alberta Health Services - Cancer Care, Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|British Columbia Cancer Agency - Kelowna, Kelowna, British Columbia, V1Y 5L3, Canada|British Columbia Cancer Agency - Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada|BC Cancer GU Clinic - Fairmont Medical Building, Vancouver, British Columbia, V5Z IH7, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, N6A 4L6, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, N6A 5W9, Canada|R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, Ontario, L1G 2B9, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|CIUSSS de l'Estrie-Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, J1H 5N4, Canada|Herlev Hospital, Onkologisk Afdeling R, Herlev, 2730, Denmark|Odense Universitetshospital, Odense C, 5000, Denmark|Centre Eugene Marquis Service Pharmacie - Essais Cliniques, Rennes, Cedex, 35042, France|Centre FRANCOIS BACLESSE, CAEN cedex 05, 14076, France|Centre Francois Baclesse, Caen, Cedex 05, 14076, France|Centre de cancerologie de la Sarthe, Le Mans, 72000, France|Centre de Cancérologie de la Sarthe (CCS) - Clinique Victor Hugo, Le Mans, 72000, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, 72000, France|Clinique Victor Hugo Centre de Cancerologie de la Sarthe, Le Mans, 72000, France|Clinique Victor Hugo, Le Mans, 72000, France|Centre Léon Bérard, Lyon cedex 8, 69008, France|Centre Léon Bérard, LYON cedex 8, 69373, France|Institut Paoli Calmettes, Marseille, 13009, France|Centre Eugene Marquis, Rennes cedex, 35042, France|Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Saint-Herblain Cedex, 44805, France|Institut de Cancerologie de Lorraine (ICL), Vandoeuvre les Nancy, 54519, France|Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, 54519, France|Institut Gustave Roussy, Villejuif, 94805, France|Universitaetsklinikum Tuebingen, Tuebingen, Baden-wuerttemberg, 072076, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Baden-wuerttemberg, 72076, Germany|Universitaetsklinikum Jena, Jena, Thuringia, 07743, Germany|Universitaetsklinikum Jena Klinik und Poliklinik fuer Urologie, Jena, Thuringia, 07747, Germany|Universitaetsklinikum Jena, Jena, Thuringia, 07747, Germany|Dél.pesti Centrumkórház-OHII Szent Lálszló Kórház telephely, Budapest, 1097, Hungary|Országos Onkológiai Intézet, Budapest, 1122, Hungary|The Chaim Sheba Medical Center, Tel-Hashomer, Ramat - GAN, 5265601, Israel|Assaf Harofe MC, Beer Yaakov, 70300, Israel|Shamir Medical Center, Beer Yaakov, 70300, Israel|Rambam Health Care Campus, Haifa, 31096, Israel|Rambam Healthcare Campus, Haifa, 31096, Israel|Meir Medical Center, Kfar Saba, 44281, Israel|Rabin Medical Center, Petach Tikva, 49100, Israel|The Chaim Sheba Medical Center, Ramat - Gan, 5265601, Israel|Pharmacy - clinical unit, Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Centro di Riferimento Oncologico - IRCCS, Aviano, (pn), 33081, Italy|Farmacia Studi Clinici, Rozzano, Milan, 20089, Italy|Istituto Clinico Humanitas, Rozzano, Milan, 20089, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy|SC Farmacia, Milan, 20133, Italy|Istituto Europeo di Oncologia, Milan, 20141, Italy|Servizio di Farmacia, Milan, 20141, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, 00152, Italy|Nagoya University Hospital, Nagoya, Aichi, 466-8560, Japan|Hirosaki University School of Medicine & Hospital, Hirosaki, Aomori, 036-8563, Japan|Hokkaido University Hospital, Sapporo, Hokkaidô, 060-8648, Japan|Iwate Medical University Hospital, Shiwa-gun, Iwate, 028-3695, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, 236-0004, Japan|Kindai University Hospital, Osakasayama, Osaka, 589-8511, Japan|Osaka University Hospital, Suita, Osaka, 565-0871, Japan|Hamamatsu University School of Medicine, University Hospital, Hamamatsu, Shizuoka, 431-3192, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, 160-8582, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, 162-8666, Japan|Akita University Hospital, Akita, 010-8543, Japan|Chiba Cancer Center, Chiba, 260-8717, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|Niigata University Medical & Dental Hospital, Niigata, 951-8520, Japan|Tokushima University Hospital, Tokushima, 770-8503, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|Clinical Trial Pharmacy, National Cancer Center, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|National Cancer Center, Goyang-Si, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Clinical Pharmacy, Seongnam-si, Gyeonggido, 13620, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggido, 13620, Korea, Republic of|Kyungpook National University Medical Center, Clinical Pharmacy, Daegu, 41404, Korea, Republic of|Kyungpook National University Medical Center, Daegu, 41404, Korea, Republic of|Chungnam National University Hospital, Clinical Pharmacy, Daejeon, 35015, Korea, Republic of|Chungnam National University Hospital, Daejeon, 35015, Korea, Republic of|Seoul National University Hospital, Clinical Pharmacy, Seoul, 03080, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Clinical Trial Pharmacy, Seoul, 05505, Korea, Republic of|Samsung Medical Center Clinical Trial Pharmacy, Seoul, 06351, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Instituto Nacional de Cancerologia, Mexico, Ciudad DE Mexico, 14080, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Centro Universitario Contra el Cancer, Monterrey, Nuevo LEON, 64460, Mexico|Oaxaca Site Management Organization S.C., Oaxaca, 68000, Mexico|Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Noord-holland, 1066 CX, Netherlands|Netherlands Cancer Institute / Apotheek MC Slotervaart, Amsterdam, Noord-holland, 1066 EC, Netherlands|VU University Medical Center (VUmc), Amsterdam, Noord-holland, 1081 BT, Netherlands|VU University Medical Center (VUmc), Amsterdam, Noord-holland, 1081 HZ, Netherlands|Sint Franciscus Gasthuis, Pharmacy, Rotterdam, Zuid-holland, 3045 PM, Netherlands|Sint Franciscus Gasthuis, Rotterdam, Zuid-holland, 3045 PM, Netherlands|Maxima Medisch Centrum, Eindhoven, 5631 BM, Netherlands|St Apotheek der Haarlemse Ziekenhuizen, Haarlem, 2035 RC, Netherlands|Spaarne Gasthuis, Hoofddorp, 2134 TM, Netherlands|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|Maxima Medisch Centrum, Veldhoven, 5504 DB, Netherlands|Maxima Medisch Centrum, Veldhoven, 5504 DL, Netherlands|Auckland City Hospital, Grafton, Auckland, 1023, New Zealand|Tauranga Hospital, Bay of Plenty Clinical Trials Unit, Tauranga, BAY OF Plenty, 3143, New Zealand|Palmerston North Hospital, Palmerston North, Manawatu- Whanganui, 4414, New Zealand|Palmerston North Hospital, Palmerston North, Manawatu-wanganui, 4414, New Zealand|Tauranga Hospital, Tauranga Bay Of Plenty, Tauranga, 3112, New Zealand|Wairarapa District Health Board, Masterton, Wairarapa, 5840, New Zealand|Auckland City Hospital Pharmacy, Auckland, 1023, New Zealand|Baxter Healthcare New Zealand, Auckland, 1060, New Zealand|Christchurch Hospital, Christchurch, 8140, New Zealand|Waikato Hospital Pharmacy Services, Hamilton, 3240, New Zealand|Waikato Hospital, Hamilton, 3240, New Zealand|Broadway Radiology, Palmerston North, 4410, New Zealand|""Prof. Dr. Ion Chiricuta"" Oncology Institute, Cluj-Napoca, 400015, Romania|S.C. Medisprof S.R.L., Cluj-Napoca, 400641, Romania|""Sfantul Nectarie"" Oncology Center, Craiova, 200347, Romania|Oncomed SRL, Timisoara, 300239, Romania|RBHI ""Kursk Regional Clinical Oncology Dispensary"" of HCKR (legal address), Kursk, Kursk Region, 305035, Russian Federation|RBHI ""Kursk Regional Clinical Oncology Dispensary"" of HCKR, Kursk, Kursk Region, 305524, Russian Federation|Russian Research Center for Radiology and Surgical Technologies, Saint Petersburg, Pesochny, 197758, Russian Federation|FSBI ""Research Institute of Oncology n.a. N.N. Petrov"" MoH RF, Saint-Petersburg, Poselok Pesochniy, 197758, Russian Federation|Private medical institution ""Euromedservice"", Pushkin, Saint-petersburg, 196603, Russian Federation|Scientific Research Institute of Urology named after N.A.Lopatkin of the Hersten Federal, Moscow, 105425, Russian Federation|Moscow Scientific Research Oncology Institute n.a. P.A. Hertzen, Moscow, 125284, Russian Federation|FBIH ""Privolzhskiy Regional Medical Center"" of FMBA, Nizhniy Novgorod, 603001, Russian Federation|SBIH of Nizhegorodskaya region ""Clinical-Diagnostics center"", Nizhniy Novgorod, 603006, Russian Federation|FBIH ""Privolzhskiy Regional Medical Center"" of FMBA, Nizhniy Novgorod, 603032, Russian Federation|FBIH ""Privolzhskiy Regional Medical Center"" of FMBA, Nizhniy Novgorod, 603109, Russian Federation|SBIH of Nizhegorodskaya region ""Nizhniy Novgorod Regional Clinical Oncology Dispensary"", Nizhniy Novgorod, 603126, Russian Federation|Clinical Hospital #122 n.a. L. G. Sokolov, Saint Petersburg, 194291, Russian Federation|NS HI ""Road Clinical Hospital of JSC ""Russian Railways"""", Saint Petersburg, 195271, Russian Federation|LLC ""Diagnostic center ""Energo"", Saint Petersburg, 196247, Russian Federation|LLC ""Clinical Diagnostic Center ""Medex-pert"", Yaroslavl, 150014, Russian Federation|SHI YR Regional Clinical Oncology Hospital, Yaroslavl, 150040, Russian Federation|Clinica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Sahlgrenska University Hospital, Dept of Oncology, Gothenburg, 413 45, Sweden|Cambridge University Hospital NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Mount Vernon Cancer Centre, East & North Herts NHS Trust, London, Middlesex, HA6 2RN, United Kingdom|Mount Vernon Cancer Centre, Pharmacy, London, Middlesex, HA6 2RN, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, London, SM2 5PT, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom|Addenbrooke's Hospital, Central Pharmacy, Level 1, Cambridge, CB2 0QQ, United Kingdom|Beatson WOSCC, Glasgow, G12 0YN, United Kingdom|Beatson West of Scotland Cancer Centre, Gartnavel General Hospital,, Glasgow, G120YN, United Kingdom|St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom|The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom|Clinical Trials Pharmacy, The Christie, Manchester, M20 4BX, United Kingdom|Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Academic Unit of Oncology, Nottingham University Hospitals NHS Trust-City Campus, Nottingham, NG5 1PB, United Kingdom|Nottingham University Hospitals, Nottingham City Hospital, Nottingham Trials Pharmacy, Nottingham, NG5 1PB, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/06/NCT02684006/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/06/NCT02684006/SAP_001.pdf"
